Duke University Medical Center is conducting a research study to learn more about the safety and effects of the combination of telaprevir, peginterferon alfa-2a (Peg-IFN) and ribavirin (RBV) in black/African American subjects with chronic hepatitis C.

Eligibility

To participate in this study, you must be an adult between the ages of 18 and 70 who:

• Has the chronic hepatitis C genotype 1
• Did not respond to previous treatment with pegylated interferon and ribavirin
• Has screening laboratory values, tests, and physical exam within acceptable ranges

Duration

If you take part in the study, your participation could last for about one-and-a-half years. This will include a screening period that could last up to 28 days, a treatment period that could last up to 48 weeks, and a follow-up period that may last up until 72 weeks after your first dose of study drug.

For more information, contact Loranda Ross at 919-681-2941 or 866-704-4673.